Octreotide Injection Shortage
Last Updated: July 3, 2024
Status: Current
Reason for the Shortage
-
- Avet has octreotide injection available.
- Fresenius Kabi has octreotide injection available.
- Hikma has octreotide injection available.
- Sagent has octreotide injection available.
- Sun Pharma discontinued Bynfezia Pen in 2021.
- Teva discontinued octreotide in April 2022.
- Viatris has octreotide injection available.
- Novartis has Sandostatin available.
Available Products
-
- Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
- Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
- Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
- Octreotide Acetate injection, Avet Pharmaceuticals, 100 mcg/mL, 1 mL vial, 10 count, NDC 23155-0688-41
- Octreotide Acetate injection, Avet Pharmaceuticals, 1000 mcg/mL, 5 mL vial, 1 count, NDC 23155-0686-31
- Octreotide Acetate injection, Avet Pharmaceuticals, 200 mcg/mL, 5 mL vial, 1 count, NDC 23155-0685-31
- Octreotide Acetate injection, Avet Pharmaceuticals, 50 mcg/mL, 1 mL vial, 10 count, NDC 23155-0687-41
- Octreotide Acetate injection, Avet Pharmaceuticals, 500 mcg/mL, 1 mL vial, 10 count, NDC 23155-0689-41
- Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
- Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
- Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
- Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
- Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
- Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-01
- Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
- Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-01
- Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
- Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
- Octreotide Acetate injection, Mylan Institutional (Viatris), 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
- Octreotide Acetate injection, Mylan Institutional (Viatris), 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
- Octreotide Acetate injection, Mylan Institutional (Viatris), 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
- Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0464-01
- Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0467-05
- Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0466-05
- Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0463-01
- Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0465-01
Estimated Resupply Dates
-
- All marketed presentations are available.
Updated
Updated July 3, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.